Skip to main content

Table 2 Difference in clinical characters between native liver survivors and other subjects in this hepatoblastoma cohort

From: Prognostic roles of pathology markers immunoexpression and clinical parameters in Hepatoblastoma

  Survive with Native liver (n = 22) Others (n = 9) p-value
Diagnostic age, medium (range), years 1 (0–10.0) 2 (1–15.0) 0.004
Male gender, n (%) 15 (68.2) 4 (44.4%) 0.25
Initial maximal tumor diameter, medium (range), cm 9.50 (4.20–20.1) 9.90 (5.0–13.0) 0.78
Initial AFP level, medium (range), log10 ng/mL 5.23 (3.33–6.16) 5.09 (1.30–6.47) 0.84
Maximal tumor size after neo-adjuvant chemotherapy, medium (range), cm 5.00 (2.6–11.0) 7.40 (1.50–12.0) 0.31
AFP level after neo-adjuvant chemotherapy, medium (range), log10 ng/mL 2.01 (1.15–4.58) 3.44 (1.18–6.55) 0.04
PRETEXT stage*, n (%)    
PRETEXT I 1 (4.55%) 0 (0%)  
PRETEXT II 10 (45.45%) 3 (33.33%)  
PRETEXT III 7 (31.82%) 3 (33.33%)  
PRETEXT IV 4 (18.18%) 3 (33.33%) 0.73
  1. *PRETEXT, PRETreatment EXTent of disease